C4 Therapeutics enters Roche DAC collaboration; $20M upfront, >$1B milestones

C4 Therapeutics, Inc.

$20M upfront from Roche for two DAC programs targeting undisclosed oncology targets.
Eligible for over $1B in discovery, regulatory, and commercial milestones plus tiered royalties (mid-single to low-double digit).
Roche responsible for all development, regulatory, manufacturing, and commercialization costs.
Option for a third target with additional payment, milestones, and royalties.
Leverages C4T's TORPEDO platform for degrader payloads and Roche's ADC expertise.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

C4 Therapeutics, Inc. entered into "License Agreement" with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, "Roche") valued at $20.0 million upfront, over $1.0 billion in aggregate milestone payments (effective 2026-04-08).

Action: entry
Agreement: collaboration
Counterparty: F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, "Roche")
Value: $20.0 million upfront, over $1.0 billion in aggregate milestone payments
Effective: 2026-04-08

Exact text from the filing

On April 8, 2026 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement ( the “ License Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Hoffmann-La Roche Inc. (“ Roche US ”, and together with Roche Basel, “ Roche ”) to collaborate on the discovery, development and commercialization of degrader-antibody conjugates (" DACs ")

View on SEC.gov

Browse all material agreements →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-024336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.